share_log

Sysmex Co. (OTCMKTS:SSMXY) Short Interest Update

kopsource ·  03/11/2023 22:44

Sysmex Co. (OTCMKTS:SSMXY – Get Rating) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 3,900 shares, a decrease of 74.8% from the February 13th total of 15,500 shares. Based on an average daily trading volume, of 54,200 shares, the short-interest ratio is presently 0.1 days.

Sysmex Price Performance

Shares of OTCMKTS:SSMXY opened at $31.42 on Friday. The company has a quick ratio of 2.07, a current ratio of 2.88 and a debt-to-equity ratio of 0.05. Sysmex has a fifty-two week low of $25.08 and a fifty-two week high of $38.98. The firm has a 50-day simple moving average of $31.48 and a 200 day simple moving average of $29.89. The company has a market cap of $13.18 billion, a PE ratio of 35.32 and a beta of 0.67.

Get Sysmex alerts:

About Sysmex

(Get Rating)

Sysmex Corp. engages in the healthcare business. It develops, manufactures, sells, exports, and imports diagnostic instruments, reagents. and software used in in-vitro diagnostics. It also provides clinical laboratory testing of blood, urine, and other specimens. Its products include instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care (POC) testing.

Featured Stories

  • Get a free copy of the StockNews.com research report on Sysmex (SSMXY)
  • MarketBeat Week in Review – 3/6 – 3/10
  • 2 Offshore Drilling Stocks Set to Extract Big Profits
  • Three Staples Stocks With Double-Digit Upside Ahead
  • Can Investors Trust Consumers to Lift American Outdoor Brands?
  • How to Buy High Yielding Dividend Stocks

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment